Résultats de la recherche

search

Rechercher les filtres

Mot-clé
car-t
WUGEN-Logo-White-Background-FIN.jpg
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
20 mars 2025 07h00 HE | Wugen
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
Allogenica.png
Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership
19 mars 2025 06h00 HE | Allogenica
Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership Allogenica received a €2.5 million grant from the French government's France...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Provides Corporate Update
18 mars 2025 16h05 HE | Cargo Therapeutics, Inc.
CARGO Therapeutics Provides Corporate Update
Notified TMP Stamp.png
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month
18 mars 2025 08h44 HE | Today's Marketplace
Today's Marketplace interviews Arcellx CMO and Creighton University to discuss multiple myeloma awareness month.
WUGEN-Logo-White-Background-FIN.jpg
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
26 févr. 2025 07h00 HE | Wugen
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
CERo color.jpg
CERo Therapeutics Holdings, Inc. Highlights Progress
06 févr. 2025 08h15 HE | CERo Therapeutics Holdings, Inc.
Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics...
CytoMed logo.png
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
06 févr. 2025 07h20 HE | CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company’s Board...
Cellectis Logo.png
Monthly information on share capital and company voting rights
04 févr. 2025 16h30 HE | Cellectis Inc.
PARIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595    DateTotal number of sharesin the capitalTotal number of voting...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Announces $55.6 Million Private Placement
27 déc. 2024 09h00 HE | Vor Biopharma
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...
CytoMed logo.png
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
20 nov. 2024 07h00 HE | CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical...